Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
Editor´s Picks
From China to the US: Best Business Practice Sharing amid the COVID-19 Pandemic(4/10/2020 )  (Premium)
  Key takeaways from a recent webinar with China-based executives discussing COVID-19 from AmCham China, including updating emergency policies, protecting and motivating the workforce, and seeking new business opportunities.
The Market
NH's DB6: Top Ten Chinese OTC Brands in 2019(4/10/2020 )  (Premium)
  Dong-e E-jiao once again led all Chinese OTC brands in terms of sales in 2019, according to topline information released to WiCON|Pharma China by Nicholas Hall & Co., which publishes the DB6 Global OTC Database.
Asia Pacific Drug Delivery Systems Market Has Promising Opportunities 2020-2027(4/10/2020 )  (Premium)
  The Asia Pacific drug delivery systems market is expected to reach US$441,337 million in 2027 from US$212,012.7 million in 2018, according to a new report from theinsightpartners.com. The market is estimated to grow with a CAGR of 8.6% from 2020-2027.
Asia Pacific and Chinese CRO Market Value Projected to Expand By 2025(4/9/2020 )  (Premium)
  The APAC contract research organization (CRO) market is expected to reach US$1,1593.7 Mn in 2025 from US$4,795.6 Mn in 2017. The market is estimated to grow with a CAGR of 11.9 % from 2020-2025. The Chinese CRO market is forecasted to reach US$4,707 million in 2025.
Nicholas Hall's Review of China's OTC Drug Market Performance 2019(4/9/2020 )  (Premium)
  OTC growth in China was 5.1% in 2019, holding steady with that in 2018, according to the new edition of Nicholas Hall's DB6 Global OTC Database, which released its topline data to WiCON|Pharma China.The overall Chinese OTC drug market reached US$ 26,219 million in 2019.
Industry News
Boehringer Ingelheim Biopharmaceuticals China Receives ¡°ISPE Facility of the Year¡± Award(4/9/2020 )  (free)
  Boehringer Ingelheim Biopharmaceuticals China has been awarded with a 2020 Facility of the Year Award (FOYA) from the International Society for Pharmaceutical Engineering (ISPE). The company received an Honorable Mention award for its commercial facility in Shanghai.
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979(4/8/2020 )  (Premium)
  Regeneron Pharmaceuticals and Zai Lab announced on April 8 a strategic collaboration for the development and commercialization of REGN1979 (CD20xCD3 bispecific antibody) in mainland China, Hong Kong, Taiwan and Macau.
GenScript ProBio and Eutilex Partner to Develop Anti-cancer Immunotherapy Technology(4/8/2020 )  (Premium)
  GenScript's CDMO business GenScript ProBio and Eutilex committed to developing anti-cancer immunotherapy technology jointly announced on April 7 that the parties entered into strategic collaboration on plasmid and virus process development and manufacturing for multiple CAR-T programs.
Immutep and EOC Continue to Advance Breast Cancer Drug Efti in China(4/7/2020 )  (Premium)
  Immutep Ltd (ASX: IMM; NASDAQ: IMMP) announced on April 8 that EOC Pharma and Immutep jointly discussed the current AIPAC results and confirmed plans to continue advancing Efti (designated as EOC202 in China) in metastatic breast cancer.
GSK and Innovax in Partnership for COVID-19 Vaccine R&D(4/7/2020 )  (Premium)
  GlaxoSmithKline has teamed up with Xiamen Innovax Biotech to evaluate a vaccine against the novel coronavirus behind the COVID-19 pandemic. The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.
Akeso Biotech Sets $300M IPO in Motion(4/7/2020 )  (Premium)
  Chinese biotech company Akeso kicked off pre-marketing of its Hong Kong initial public offering that could raise up to US$300 million (HK$2.34 billion) on April 5.
Regulatory News
CDE Solicits Public Comments for Clinical Research Guidelines for Bevacizumab Biosimilars(4/10/2020 )  (Premium)
  The CDE issued on April 7 the Clinical Research Guidelines for Denosumab Biosimilars on March 1 for public comments. Denosumab¡¯s originator is Amgen and its brand is Prolia, which was approved in China in May 2019.
CDE Solicits Public Comments for Clinical Research Guidelines for Trastuzumab Biosimilars(4/7/2020 )  (Premium)
  The CDE issued on April 7 the Clinical Research Guidelines for Trastuzumab Biosimilars on March 1 for public comments. Trastuzumab¡¯s originator is Roche and its brand is Herceptin.
CDE Solicits Public Comments for Clinical Research Guidelines for Bevacizumab Biosimilars(4/7/2020 )  (Premium)
  The CDE issued on April 7 the Clinical Research Guidelines for Bevacizumab Biosimilars on March 1 for public comments. Bevacizumab¡¯s originator is Roche¡¯s Genentech and its brand is Avastin.
General Health
Infectious Diseases in Children and Adolescents in China: Analysis of National Surveillance Data from 2008 to 2017(4/9/2020 )  (Premium)
  A recent study by Chinese researchers, with abstract published on the BMJ, attempts to outline which infectious diseases in the pre-covid-19 era persist in children and adolescents in China and to describe recent trends and variations by age, sex, season, and province.
Product/R&D News
China Recruits Volunteers for Phase 2 Coronavirus Vaccine Trial(4/9/2020 )  (Premium)
  Barely a week after Chinese scientists finished injecting an experimental coronavirus vaccine into their first group of volunteers, official news outlets reported on April 9 that a second batch of participants was being recruited.
API/Bulk Drug News
India Lifts Export Restrictions on 24 APIs(4/7/2020 )  (Premium)
  The Indian government removed export restrictions on April 6 for 24 APIs and their formulations. These include Tinidazole, Metronidazole, Acyclovir, Vitamin BI, Vitamin B6, and Vitamin B12. Restrictions on paracetamol have however not been lifted yet.
People in the News
Recent Executive Moves(4/10/2020 )  (Premium)
  Chinese pharma-related executive movements at companies including GSK China, Pfizer China and Genesis Medtech.
© Wicon International Group¡¡Support by: www.heightow.com Home | Site map | Contact Us | Links